Affordable Access

Access to the full text

RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study

Authors
  • Chen, Shih-Hsin1
  • Wang, Hung-Ming2
  • Lin, Chien-Yu3
  • Chang, Joseph Tung-Chieh3
  • Hsieh, Chia-Hsun2
  • Liao, Chun-Ta4
  • Kang, Chung-Jan4
  • Yang, Lan-Yan5
  • Yen, Tzu-Chen1
  • 1 Chang-Gung Memorial Hospital, Linkou, Department of Nuclear Medicine, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, 333, Taiwan , TaoYuan County (Taiwan)
  • 2 Chang-Gung Memorial Hospital, Linkou, Division of Hematology/Oncology, Department of Internal Medicine, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, 333, Taiwan , TaoYuan County (Taiwan)
  • 3 Chang-Gung Memorial Hospital, Linkou, Department of Radiation Oncology, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, 333, Taiwan , TaoYuan County (Taiwan)
  • 4 Chang-Gung Memorial Hospital, Linkou, Departments of Otorhinolaryngology, Head and Neck Surgery, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, 333, Taiwan , TaoYuan County (Taiwan)
  • 5 Chang-Gung Memorial Hospital, Linkou, Clinical Trial Center, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, 333, Taiwan , TaoYuan County (Taiwan)
Type
Published Article
Journal
European Journal of Nuclear Medicine
Publisher
Springer-Verlag
Publication Date
Feb 27, 2016
Volume
43
Issue
9
Pages
1621–1629
Identifiers
DOI: 10.1007/s00259-016-3345-1
Source
Springer Nature
Keywords
License
Yellow

Abstract

Background/AimWe prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT).Patients and MethodsNewly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment).ResultsNine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors.ConclusionRGD-K5 PET has the potential to identify patients with incomplete responses to CCRT.

Report this publication

Statistics

Seen <100 times